多西他赛联合洛铂新辅助化疗方案治疗三阴性乳腺癌的临床观察

目的 探讨多西他赛联合洛铂在三阴性乳腺癌（TNBC）新辅助化疗中的疗效和不良反应。方法30例TNBC患者应用多西他赛联合洛铂行新辅助化疗，具体方案为：多西他赛75mg／m²静滴，d1；洛铂30mg／m²静滴，d1；21天为1周期。按照WHO实体瘤客观疗效评价标准及术后病理组织学检测评价疗效，按照WHO急性及亚急性毒性标准评价毒副反应。结果8、17和5例患者分别完成2、4和6个周期的新辅助化疗，获CR 9例、PR 15例、SD 4例、PD 2例，RR为80.0％；术后病理组织学检测获病理学完全缓解6例。主要不良反应为骨髓抑制：1～2级白细胞减少17例，3～4级5例；1～2级血小板减少7例，3～4级2例；1～2级血红蛋白减少6例。非血液学毒性轻微。结论 多西他赛联合洛铂方案的疗效较好，毒副反应可耐受，是TNBC新辅助化疗方案的一个新选择。

Clinical observation of neoadjuvant chemotherapy with docetaxel plus lobaplatin regimen in triple negative breast cancer

Objective To evaluate the efficacy and adverse reaction of neoadjuvant chemotherapy with docetaxel plus lobapla- tin regimen in triple negative breast cancer （TNBC）. Methods Thirty TNBC patients accepted neoadjuvant chemotherapy with do- cetaxel and lobaplatin（ docetaxel 75mg,/m2 iv, dI ; lobaplatin 30mg/m2 iv, d1 ; 21 days was a cycle）. The objective response and side effects were evaluated by WHO standard or histopathological reaction after surgery. Results Eight patients finished chemotherapy for 2 cycles, 17 patients for 4 cycles and 5 patients for 6 cycles. All patients were evaluable, 9 cases got CR, 15 cases got PR, 4 cases had SD, 2 cases were PD. The clinical benefit rate was 80. 0%. Six cases achieved pCR according to the histopathological detection after surgery. The main adverse reaction was myelosuppression,with grade 1-2 leukopenia in 17 cases, grade 3-4 leukopenia in 5 cases, grade 1-2 thrombocytopenia in 7 cases, grade 3-4 thrombocytopenia in 2 cases and grade 1-2 anemia in 6 cases. Non-hemotologic toxic- ities were modest and recoverable. Conclusion Neoadjuvant chemotherapy with docetaxel plus lobaplatin regimen in TNBC is effective and well tolerated,which gives us a new choice.